InfuSystem (NYSE:INFU) Upgraded to “Strong-Buy” at B. Riley

B. Riley upgraded shares of InfuSystem (NYSE:INFU) to a strong-buy rating in a report issued on Wednesday, Zacks.com reports.

Separately, StockNews.com raised shares of InfuSystem from a buy rating to a strong-buy rating in a research report on Friday, September 20th.

InfuSystem Price Performance

Shares of INFU opened at $6.57 on Wednesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.64 and a current ratio of 2.07. InfuSystem has a 1-year low of $5.74 and a 1-year high of $10.99. The firm has a market cap of $140.07 million, a PE ratio of -657,000.00 and a beta of 1.46.

InfuSystem (NYSE:INFU) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). InfuSystem had a net margin of 0.28% and a return on equity of 0.70%. The firm had revenue of $33.70 million for the quarter.

Institutional Investors Weigh In On InfuSystem

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INFU. Rhumbline Advisers lifted its holdings in shares of InfuSystem by 13.8% in the 2nd quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock valued at $121,000 after buying an additional 2,145 shares during the period. Marshall Wace LLP acquired a new position in InfuSystem in the second quarter valued at approximately $131,000. Oppenheimer Asset Management Inc. boosted its position in InfuSystem by 52.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company’s stock worth $178,000 after purchasing an additional 8,917 shares in the last quarter. Panagora Asset Management Inc. purchased a new position in shares of InfuSystem during the 2nd quarter valued at approximately $208,000. Finally, ARS Investment Partners LLC lifted its stake in shares of InfuSystem by 11.4% in the 2nd quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock valued at $229,000 after purchasing an additional 3,422 shares during the period. 71.13% of the stock is owned by institutional investors and hedge funds.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.